A detailed history of Vident Advisory, LLC transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Vident Advisory, LLC holds 13,933 shares of HRMY stock, worth $474,557. This represents 0.01% of its overall portfolio holdings.

Number of Shares
13,933
Previous 21,298 34.58%
Holding current value
$474,557
Previous $643 Million 13.27%
% of portfolio
0.01%
Previous 0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$30.0 - $39.95 $220,950 - $294,231
-7,365 Reduced 34.58%
13,933 $557 Million
Q2 2024

Aug 14, 2024

BUY
$28.81 - $33.01 $613,595 - $703,046
21,298 New
21,298 $643 Million
Q4 2023

Feb 14, 2024

SELL
$19.2 - $33.78 $106,156 - $186,769
-5,529 Reduced 46.69%
6,312 $204 Million
Q3 2023

Feb 21, 2024

BUY
$31.89 - $39.03 $176,319 - $215,796
5,529 Added 87.6%
11,841 $388 Million
Q3 2023

Nov 14, 2023

BUY
$31.89 - $39.03 $377,609 - $462,154
11,841 New
11,841 $388 Million

Others Institutions Holding HRMY

About Harmony Biosciences Holdings, Inc.


  • Ticker HRMY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,161,400
  • Market Cap $2.02B
  • Description
  • Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...
More about HRMY
Track This Portfolio

Track Vident Advisory, LLC Portfolio

Follow Vident Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vident Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vident Advisory, LLC with notifications on news.